Welcome to our dedicated page for BRUKER SEC filings (Ticker: BRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bruker Corporation filings document financial results, capital returns, governance actions and proxy matters for a scientific instruments and diagnostics company.
Recent Form 8-K disclosures cover quarterly and annual operating results, outlook commentary, segment information for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, and dividends on common stock and 6.375% Mandatory Convertible Preferred Stock, Series A. The definitive proxy statement covers board elections, executive compensation, pay-versus-performance data, shareholder voting items and governance practices. Other material-event filings record board composition changes and executive transition arrangements.
Mark R. Munch filed a Form 144 indicating a plan to sell 2,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $115,200.00 as of August 14, 2026. The planned sale is related to a stock option exercise for cash. Over the prior three months, Mark R. Munch reported selling 2,000 shares of common stock on each of May 15, June 15, and July 15, 2026, for aggregate prices of $87,800.00, $109,520.00, and $120,500.00, respectively.
Bruker Corporation announced that its Board of Directors has declared a quarterly cash dividend on its common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on August 14, 2026 and is payable on October 7, 2026 to shareholders of record at the close of business on September 21, 2026.
BRUKER CORP executive Mark Munch, Executive Vice President and President of Bruker Nano Inc., reported a Form 4 transaction involving company common stock. On 2026-08-11, 1,619 shares of common stock were withheld by the company at $57.02 per share to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this tax-withholding disposition, Munch directly holds 123,347 shares of BRUKER CORP common stock.
BRUKER CORP executive vice president and CFO Gerald N. Herman reported a Code F transaction involving 1,410 shares of common stock on 2026-08-11. According to the company’s disclosure, these shares were withheld to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, rather than sold in an open-market transaction. Following this tax-withholding disposition, Herman’s directly held ownership stands at 98,284 shares of BRUKER CORP common stock.
BRUKER CORP President & CEO Frank H. Laukien reported a Form 4 reflecting a code F transaction in the company’s common stock. On 2026-08-11, 4,838 shares were withheld by the company at $57.02 per share to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. After this withholding, Laukien directly holds 38,482,340 common shares. The filing also lists various indirect holdings for family members, including 336,607 shares held indirectly “By Daughter.”
BRUKER CORP executive Mark Munch, Executive VP and President of Bruker Nano Inc., reported two Form 4 transactions involving Common Stock coded "F". On 2026-08-10, 1,573 shares were withheld at $56.32 per share, and on 2026-08-09, 1,904 shares were withheld at $53.41 per share. According to the footnote, these 3,477 shares were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, rather than discretionary market sales.
BRUKER CORP executive Gerald N. Herman, Executive Vice President and CFO, reported two transactions in company common stock. On August 9, 2026, and August 10, 2026, a total of 2,889 shares were withheld by the company at prices of $53.41 and $56.32 per share, respectively. According to the disclosure, these shares were withheld solely to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, rather than representing open-market sales.
BRUKER CORP President & CEO Frank H. Laukien reported two Form 4 transactions involving common stock used to cover taxes on equity compensation. On 2026-08-10, 4,564 shares were withheld at $56.32 per share, and on 2026-08-09, 2,361 shares were withheld at $53.41 per share. A footnote states these shares were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, rather than sold in open-market trades. The filing also lists several indirect ownership positions held through or for family members, including 336,607 shares held indirectly by a daughter after the reported date.
FMR LLC and Abigail P. Johnson report significant ownership of BRUKER CORP common stock. FMR LLC is listed with 23,296,465.55 shares beneficially owned, representing 15.0% of the class. FMR LLC has 17,974,598.38 shares with sole voting power and 23,296,465.55 shares with sole dispositive power, with no shared voting or dispositive power reported.
Abigail P. Johnson is also reported as a beneficial owner of 23,296,465.55 shares, equal to 15.0% of the class, with sole dispositive power and no voting or shared powers listed. One or more other persons have rights to dividends or sale proceeds tied to these shares, but no single such person holds more than five percent of BRUKER CORP’s outstanding common stock.
Bruker Corporation reported Q2 2026 revenue of $838.5 million, up from $797.4 million, with growth across BSI CALID, BSI NANO, and BEST. Gross profit rose to $416.0 million, but a $134.9 million goodwill impairment and other charges drove a consolidated operating loss of $65.3 million. After interest and other income of $24.6 million, taxes, and $10.9 million of preferred dividends, net loss attributable to common shareholders was $62.9 million, or $(0.41) per share, versus $0.05 earnings a year earlier.
For the first half of 2026, revenue was $1,661.9 million and net loss to common shareholders was $59.4 million. Bruker deployed $81.1 million of consideration (net of cash acquired) on acquisitions, including the remaining 60% of Tofwerk, adding goodwill of $35.4 million and identifiable intangibles (technology $42.7 million, customer relationships $3.5 million, tradename $1.6 million). Total goodwill decreased to $1,429.8 million after impairments of $98.4 million for the CST reporting unit and $36.5 million for the BSB reporting unit. Operating cash flow was a $6.2 million use, compared with $62.5 million use a year earlier; cash, cash equivalents and restricted cash were $189.1 million, and long-term debt was $1,814.7 million. Remaining performance obligations reached $2,775.6 million, and a post‑June 30 reorganization into BIOS, BMID, BSI NANO, and BEST will trigger an interim goodwill impairment analysis in the third quarter of 2026.